Rapid Therapeutic Science Stock Probability of Future Pink Sheet Price Finishing Under 6.89E-4
| RTSL Stock | USD 0 0.00 0.00% |
Rapid |
Rapid Therapeutic Target Price Odds to finish below 6.89E-4
The tendency of Rapid Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 0.0007 or more in 90 days |
| 0 | 90 days | 0.0007 | about 16.01 |
Based on a normal probability distribution, the odds of Rapid Therapeutic to drop to $ 0.0007 or more in 90 days from now is about 16.01 (This Rapid Therapeutic Science probability density function shows the probability of Rapid Pink Sheet to fall within a particular range of prices over 90 days) . Probability of Rapid Therapeutic Science price to stay between $ 0.0007 and its current price of $0.001 at the end of the 90-day period is about 6.84 .
Given the investment horizon of 90 days Rapid Therapeutic Science has a beta of -4.81 indicating as returns on its benchmark rise, returns on holding Rapid Therapeutic Science are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Rapid Therapeutic is expected to outperform its benchmark. In addition to that Rapid Therapeutic Science has an alpha of 2.5893, implying that it can generate a 2.59 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Rapid Therapeutic Price Density |
| Price |
Predictive Modules for Rapid Therapeutic
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Rapid Therapeutic Science. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Rapid Therapeutic's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Rapid Therapeutic Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Rapid Therapeutic is not an exception. The market had few large corrections towards the Rapid Therapeutic's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Rapid Therapeutic Science, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Rapid Therapeutic within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 2.59 | |
β | Beta against Dow Jones | -4.81 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.08 |
Rapid Therapeutic Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Rapid Therapeutic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Rapid Therapeutic Science can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Rapid Therapeutic is way too risky over 90 days horizon | |
| Rapid Therapeutic has some characteristics of a very speculative penny stock | |
| Rapid Therapeutic appears to be risky and price may revert if volatility continues | |
| Rapid Therapeutic Science currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 1.13, which is about average as compared to similar companies. Rapid Therapeutic Science has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rapid Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Rapid Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rapid Therapeutic Science sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rapid to invest in growth at high rates of return. When we think about Rapid Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 534. Net Loss for the year was (2.87 M) with profit before overhead, payroll, taxes, and interest of 334. | |
| Rapid Therapeutic Science currently holds about 112.16 K in cash with (2.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of Rapid Therapeutic outstanding shares are owned by corporate insiders |
Rapid Therapeutic Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Rapid Pink Sheet often depends not only on the future outlook of the current and potential Rapid Therapeutic's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Rapid Therapeutic's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.4 M | |
| Cash And Short Term Investments | 192.5 K |
Rapid Therapeutic Technical Analysis
Rapid Therapeutic's future price can be derived by breaking down and analyzing its technical indicators over time. Rapid Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Rapid Therapeutic Science. In general, you should focus on analyzing Rapid Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.
Rapid Therapeutic Predictive Forecast Models
Rapid Therapeutic's time-series forecasting models is one of many Rapid Therapeutic's pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Rapid Therapeutic's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.
Things to note about Rapid Therapeutic Science
Checking the ongoing alerts about Rapid Therapeutic for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Rapid Therapeutic Science help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Rapid Therapeutic is way too risky over 90 days horizon | |
| Rapid Therapeutic has some characteristics of a very speculative penny stock | |
| Rapid Therapeutic appears to be risky and price may revert if volatility continues | |
| Rapid Therapeutic Science currently holds 150 K in liabilities with Debt to Equity (D/E) ratio of 1.13, which is about average as compared to similar companies. Rapid Therapeutic Science has a current ratio of 0.07, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Rapid Therapeutic until it has trouble settling it off, either with new capital or with free cash flow. So, Rapid Therapeutic's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Rapid Therapeutic Science sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Rapid to invest in growth at high rates of return. When we think about Rapid Therapeutic's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 534. Net Loss for the year was (2.87 M) with profit before overhead, payroll, taxes, and interest of 334. | |
| Rapid Therapeutic Science currently holds about 112.16 K in cash with (2.21 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of Rapid Therapeutic outstanding shares are owned by corporate insiders |
Other Information on Investing in Rapid Pink Sheet
Rapid Therapeutic financial ratios help investors to determine whether Rapid Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rapid with respect to the benefits of owning Rapid Therapeutic security.